Health Canada NHP Labelling: 2026 Interchangeable Terms Explained

Health Canada has updated its List of Interchangeable Terms for Natural Health Products (NHPs), giving manufacturers greater flexibility in certain labelling and claims. The August 20, 2026 update expands the use of interchangeable terminology and clarifies that the list is not exhaustive for NHPs and applicable List D non-prescription drugs (NPDs).
For NHP manufacturers, importers, brand owners, Product Licence holders, and companies preparing products for the Canadian market, the update may make it easier to use clear, consumer-friendly wording while maintaining the meaning of authorized product information.
This article explains what changed, what the updated approach means for NHP labelling and claims, what companies should review, and how to apply the flexibility without changing the regulatory meaning of an authorized product.

What Is Health Canada’s List of Interchangeable Terms?
Health Canada introduced the List of Interchangeable Terms in November 2025 to support more flexible labelling options for NHPs and certain NPDs. The List identifies alternative terms that may be used when they convey the same meaning as the authorized terminology.
The purpose is not to change what a product is authorized to do. Instead, it provides flexibility to communicate authorized information using wording that may be clearer, more understandable, or more practical for consumers.
The August 2026 update expands this approach and gives companies greater flexibility in how they evaluate equivalent terminology.

What Changed in August 2026?
Health Canada’s August 20, 2026 update introduced three important changes for companies responsible for NHP labelling and related regulatory content.
1. Interchangeable Terms Can Now Apply to NHP Claims
One of the most significant changes is that interchangeable terminology may now be applied to NHP uses and indications. This means certain authorized NHP claims can benefit from the flexibility provided by the updated framework.
For example, a company may be able to use clearer consumer-facing terminology when the alternative wording retains the same regulatory meaning as the authorized claim.
However, interchangeable terminology should not be used to strengthen, broaden, or otherwise change the therapeutic implication of a claim. A wording change that makes a product appear more effective, faster acting, or more therapeutic, is not simply a terminology change.
2. The Flexible Approach Extends to Certain List D NPDs
The updated approach also applies to low-risk NPDs on List D when the products follow the applicable Health Canada monographs. This is particularly relevant for organizations managing portfolios that include both NHPs and certain non-prescription products.
The regulatory framework is not identical for all NPDs, so companies should confirm the regulatory status of the specific product before applying the interchangeable-term approach.
3. The List Is Not Exhaustive for NHPs and List D NPDs
Health Canada has clarified that the terminology shown in the table represents examples rather than an exhaustive list for NHPs and applicable List D NPDs.
This means companies may consider alternative wording outside the table when the proposed term is genuinely equivalent and satisfies applicable requirements.
The practical question is therefore no longer simply, “Is this exact word listed by Health Canada?” It is also, “Does this alternative wording convey the same meaning in this specific regulatory context?”
Greater Flexibility Does Not Mean Greater Freedom to Change the Label
The updated List should not be interpreted as permission to modify authorized product information without appropriate regulatory assessment.

Health Canada’s update states that interchangeable terms must convey the same meaning as the authorized term and must not be false or misleading. The terminology must also remain consistent with applicable legislation, regulations, guidance, monographs, and mandatory labelling requirements.

This is especially important for:
Uses and indications
Health claims
Warnings and cautions
Directions for use
Risk-related statements
Mandatory label information
Product Facts Tables
Canadian Drug Facts Tables
Advertising and promotional materials

A word that appears synonymous in everyday language may not necessarily have the same regulatory meaning in a particular sentence. Context matters. Companies should therefore avoid treating interchangeable terminology as a simple “find and replace” exercise.
Why the 2026 Update Matters for NHP Companies

For companies selling or preparing to sell Natural Health Products in Canada, labelling can be both a regulatory and operational challenge. A product may have an NPN, approved uses and indications, monograph-based claims, mandatory label elements, consumer-facing marketing language, multiple product formats, and packaging already printed or in production.
The revised framework may reduce some of the friction associated with equivalent wording changes. Companies may be able to improve readability and consistency across packaging without treating every equivalent wording variation as a substantive regulatory change.

For businesses managing multiple NHP products, the update may also create an opportunity to establish more consistent terminology across a product portfolio.

What About Existing NHP Labels?
Use of the List is optional, and Health Canada’s August 2026 update does not mean that companies must automatically revise existing labels simply because the List has changed.
A practical approach is to incorporate the revised framework into the normal label review and artwork-update process.
When a product is already scheduled for a packaging refresh, companies can review:
Existing authorized terminology
Current label wording
Uses and indications
Mandatory statements
Applicable monographs
Product Facts Table requirements
Consumer comprehension
Consistency across the product portfolio
This approach can allow companies to take advantage of the updated flexibility without creating unnecessary regulatory or packaging work.

Does Using an Interchangeable Term Require a Health Canada Filing?
For NHPs, the updated framework may allow use of interchangeable terminology without a notification or post-licence change in applicable circumstances. However, companies should not assume that every wording change is treated identically.
Health Canada identifies circumstances in which label mock-ups and/or leaflets have been reviewed and approved before licensing. This can be relevant to certain products, including applicable nicotine replacement therapy products.

Before implementing a wording change, companies should establish:

What type of product is this?
What information was included in the original regulatory authorization?
Were label mock-ups reviewed before licensing?
Does the proposed change affect an authorized claim or other regulated information?
Is a filing, notification, or amendment required?

A short regulatory assessment before printing new packaging can help prevent costly corrections later.
NHP Claims Require Particular Attention
The expansion to NHP claims makes the 2026 update especially relevant for companies developing new products or updating existing labels and marketing materials.

Claims are among the most commercially important elements of an NHP label, but wording can also have significant regulatory implications. A seemingly small change can alter:
The strength of the claim
The implied benefit
The intended use
Consumer interpretation
The relationship between the claim and supporting evidence

The revised interchangeable-term framework provides additional flexibility, but it does not remove the need for claim substantiation and regulatory assessment.
Replacing a technical expression with a consumer-friendly equivalent may be appropriate when the meaning remains identical. Changing wording to make a product sound more effective, faster acting, stronger, or more therapeutic would be a different matter.
Marketing and regulatory teams should therefore work together when implementing the new flexibility.

What Should NHP Manufacturers Do Now?
1. Review Your Current NHP Labels
Identify wording that is technical, difficult for consumers to understand, inconsistent across products, different from language used in marketing materials, or due for revision during an upcoming artwork update.
2. Compare Wording Against the Updated Health Canada Framework
Review the revised List of Interchangeable Terms and determine whether an alternative expression may be appropriate. For NHPs and applicable List D NPDs, also consider whether an equivalent term outside the table may be used under the clarified non-exhaustive approach.
3. Review Claims Separately
Do not assume that an interchangeable term is automatically appropriate simply because it sounds similar. Assess proposed wording against the authorized claim, applicable monograph, supporting evidence, product classification, and intended consumer interpretation.
4. Check Mandatory Label Elements
Certain elements have specific requirements and should not be modified simply because similar wording appears elsewhere in the List. Health Canada places restrictions on changes to titles, headings, and subheadings of the Canadian Drug Facts Table and Product Facts Table, subject to specified exceptions.
5. Document the Regulatory Rationale
For companies managing multiple products, maintaining an internal record explaining why an alternative term was considered equivalent can support a consistent and defensible review process across labels, packaging, websites, and advertising.

A Broader Trend Toward Greater Regulatory Flexibility
The interchangeable-terms update is part of a broader series of regulatory tools and changes introduced by Health Canada. In November 2025, the NNHPD introduced the Monograph Combination Guide and the original List of Interchangeable Terms.
The August 2026 update builds on that direction by providing greater flexibility while retaining the core requirement that product information remain accurate, compliant, and consistent with the applicable authorization.
For companies entering the Canadian market, staying current with these developments can provide a meaningful regulatory and operational advantage.

Frequently Asked Questions About Health Canada NHP Interchangeable Terms
What are Health Canada’s interchangeable terms?
Answer: They are alternative terms that may be used when they convey the same meaning as authorized terminology, subject to the applicable requirements.
Can interchangeable terms be used for NHP claims?
Answer: Yes. The August 2026 update allows the interchangeable-term approach to apply to NHP uses and indications, provided the alternative wording maintains the same meaning and remains compliant.
Is Health Canada’s List of Interchangeable Terms exhaustive?
Answer: For NHPs and applicable List D NPDs, Health Canada clarified that the table provides examples and is not intended to be exhaustive.
Do existing NHP labels need to be changed?
Answer: No. Use of the List is optional. Companies can consider the updated approach during routine label reviews and planned artwork changes.
Does every interchangeable-term change require a Health Canada filing?
Answer: Not necessarily. The applicable regulatory pathway depends on the product, its authorization history, and the type of information being changed. A product-specific assessment is recommended before implementation.
Can an interchangeable term change the meaning of an NHP claim?
Answer: No. The alternative wording must convey the same meaning as the authorized term and must not create a false or misleading impression.

How Fiducia Globus Can Help with Health Canada NHP Labelling
Understanding Health Canada’s interchangeable-term framework is only one part of maintaining a compliant NHP label. The key question for manufacturers and brand owners is how the updated approach applies to the specific product, claim, label, and regulatory authorization.
Fiducia Globus supports companies entering or operating in Canada with practical regulatory and quality services, including:
NHP product classification and regulatory strategy
Natural Health Product Licence Application (NPN) support
Health Canada NHP label and packaging reviews
NHP claims and indications review
Monograph and ingredient assessment
Regulatory gap assessments
Post-licensing regulatory support
Canadian market-entry strategy
Compliance review of product information and marketing language
Ongoing regulatory monitoring and interpretation
For companies with existing NHP portfolios, a regulatory label review can also identify opportunities to simplify consumer-facing language while keeping changes aligned with Health Canada’s requirements.
The goal is not simply to make a label “look compliant.” It is to build a regulatory approach that supports compliant commercialization, efficient product maintenance, and long-term access to the Canadian market.

Final Takeaway
Health Canada’s August 2026 update to the List of Interchangeable Terms gives NHP companies greater flexibility to use clear and consumer-friendly language while maintaining the meaning of authorized product information.
The key developments are the ability to apply interchangeable terminology to NHP claims, the extension of the flexible approach to applicable List D NPDs, and the clarification that the list is not exhaustive for NHPs and applicable List D NPDs.
The fundamental principle remains unchanged: greater flexibility in wording does not mean greater flexibility in meaning.
Companies should continue to evaluate proposed wording against the product’s market authorization, applicable Health Canada guidance, monographs, claims, and mandatory labelling requirements.